Although more work is required to confirm this concept, we found that inhibition of 1C metabolism alone or in combination with TKI therapy increased the fraction of CML CD34+ cells found in the S-G2-M phase, with a hint of decrease in the fraction of quiescent (G0) cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.